Drug Profile
Research programme: cancer and infectious diseases vaccines - Immunomedics/Alexis Biotech
Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Alexis Biotech; Immunomedics
- Class Peptides; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)